Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
Lenvatinib, an oral multikinase inhibitor, is a first-line drug for the treatment of unresectable hepatocellular carcinoma. Here, we report a case of a 72-year-old man who presented with severe generalized erythematous rash (GER) approximately four weeks after the commencement of lenvatinib treatmen...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
PAGEPress Publications,
2022-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|